New Challenges in Consent and Informed Consent in Society: Implantable Life-saving Medical Devices


New Challenges in Consent and Informed Consent in Society: Implantable Life-saving Medical Devices


Dennis J. Mazur, MD, PhD

Senior Scholar, Center for Ethics in Health Care, Oregon Health and Science University (OHSU), Professor of Medicine (OHSU)


International Journal of social research

Because of the success of keeping people alive after a life-threatening arrhythmia, the implantable cardiac defibrillator (ICD) has become an invasive medical device posing unique challenges to patients, physicians, and healthcare personnel. This paper examines the unique societal challenges of the ICD in the context of consent and informed consent in the Great Britain, the United States, Canada, and Australia. The main societal issues in consent and informed consent regarding implantable life-saving medical devices involve the types of information (individual vs. societal) that are to drive the discussion between patient and his or her physician.


Keywords: New Challenges, Consent and Informed Consent, Implantable Life-saving Medical Devices

Free Full-text PDF


How to cite this article:
Dennis J. Mazur. New Challenges in Consent and Informed Consent in Society: Implantable Life-saving Medical Devices. International Journal of Social Research, 2017; 1:2. DOI:10.28933/ijsr-2017-11-0303


References:

1 Slater v. Baker and Stapleton (1767) 2 WILS. K.B. 359, 95 Eng. Rep., 860.
2 Salgo v. Leland Stanford Junior University Board of Trustees (1957) 154 Cal. App. 2d 560.
3 Canterbury v. Spence (D.C. Cir. 1972) 464 F.2d 772.
4 Reibl v. Hughes (1980) 2 S.C.R. 880.
5 Rogers v. Whitaker (1992) 175 CLR 479.
6 Montgomery v. Lanarkshire Health Board (11 March 2015). UKSC 11.
7 Friedman PA, Bradley D, Koestler C, Slusser J, Hodge D, Bailey K, Kusumoto F, Munger TM, Militanu A, Glikson M.
8 A prospective randomized trial of single- or dual-chamber implantable cardioverter-defibrillators to minimize inappropriate shock risk in primary sudden cardiac death prevention. Europace. 2014 Oct;16(10):1460-8.
9 Bongiorni MG, Viani S, Zucchelli G, Di Cori A, Segreti L, Paperini L, Levorato D, Boem A, Branchitta G, Andreini D, Soldati E. Subcutaneous implantable cardiac defibrillators: indications and limitations. Curr Heart Fail Rep. 2015 Feb;12(1):79-86.
10 Lin YS, Hung SP, Chen PR, Yang CH, Wo HT, Chang PC, Wang CC, Chou CC, Wen MS, Chung CM, Chen TH.
11 Risk factors influencing complications of cardiac implantable electronic device implantation: infection, pneumothorax and heart perforation: a nationwide population-based cohort study. Medicine (Baltimore). 2014 Dec;93(27):e213.
12 Ruwald MH, Okumura K, Kimura T, Aonuma K, Shoda M, Kutyifa V, Ruwald AC, McNitt S, Zareba W, Moss AJ.
13 Syncope in high-risk cardiomyopathy patients with implantable defibrillators: frequency, risk factors, mechanisms, and association with mortality: results from the multicenter automatic defibrillator implantation trial-reduce inappropriate therapy (MADIT-RIT) study. Circulation. 2014 Feb 4;129(5):545-52.
14 Sadarmin PP, Wong KC, Rajappan K, Bashir Y, Betts TR. Barriers to patients eligible for screening investigations and insertion of primary prevention implantable cardioverter defibrillators. Europace. 2014 Nov;16(11):1575-9.
15 DeWitt ES, Triedman JK, Cecchin F, Mah DY, Abrams DJ, Walsh EP, Gauvreau K, Alexander ME. Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy. Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1057-63.
16 Peck KY, Lim YZ, Hopper I, Krum H. Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of > 35,000 patients. Int J Cardiol. 2014 May 1;173(2):197-203.
17 Setoguchi S, Warner Stevenson L, Stewart GC, Bhatt DL, Epstein AE, Desai M, Williams LA, Chen CY.
18 Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: cohort study of older patients with heart failure. BMJ. 2014 May 8;348:g2866.
19 Pedersen SS, Sears SF, Burg MM, Van Den Broek KC. Does ICD indication affect quality of life and levels of distress? Pacing Clin Electrophysiol. 2009 Feb;32(2):153-6.
20 Van Den Broek KC, Habibović M, Pedersen SS. Emotional distress in partners of patients with an implantable cardioverter defibrillator: a systematic review and recommendations for future research.
21 Pacing Clin Electrophysiol. 2010 Dec;33(12):1442-50.
22 Pedersen SS, VAN DEN Berg M, Erdman RA, VAN Son J, Jordaens L, Theuns DA. Increased anxiety in partners of patients with a cardioverter-defibrillator: the role of indication for ICD therapy, shocks, and personality.
23 Pacing Clin Electrophysiol. 2009 Feb;32(2):184-92.
24 Pokorney SD, Hellkamp AS, Yancy CW, Curtis LH, Hammill SC, Peterson ED, Masoudi FA, Bhatt DL, Al-Khalidi HR, Heidenreich PA, Anstrom KJ, Fonarow GC, Al-Khatib SM. Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients. Circ Arrhythm Electrophysiol. 2015 Feb;8(1):145-51.
25 Schaer BA, Kühne MS, Blatter D, Osswald S, Sticherling C. Application of a mortality risk score in a general population of patients with an implantable cardioverter defibrillator (ICD). Heart. 2014 Mar;100(6):487-91.
26 Lee DS, Hardy J, Yee R, Healey JS, Birnie D, Simpson CS, Crystal E, Mangat I, Nanthakumar K, Wang X, Krahn AD, Dorian P, Austin PC, Tu JV; Investigators of the Ontario ICD Database. Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators. Circ Heart Fail. 2015 Sep;8(5):927-37.